Dengue vaccine is under clinical development by Indian Immunologicals and currently in Phase I for Dengue Fever. According to GlobalData, Phase I drugs for Dengue Fever have a 52% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Dengue vaccine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Dengue vaccine overview
Vaccine is under development for the prevention of dengue fever. It is a recombinant vector vaccine. It is administered through subcutaneous route.
Indian Immunologicals overview
Indian Immunologicals (IIL), a subsidiary of National Dairy Development Board, manufactures and commercializes human health and animal health vaccines. The company provides human health vaccines for rabies, tetanus, diphtheria, pertussis, and hepatitis-B. Its underdevelopment product pipeline includes vaccines for hepatitis A, chikungunya, Japanese encephalitis, measles rubella, dengue, and others. IIL also provides animal health products such as vaccines; formulations including anti-infectives, anti-parasiticides, NSAIDs; nutraceuticals; over-the-counter (OTC), and generics. The company operates manufacturing units in India and New Zealand. IIL is headquartered in Hyderabad, Telangana, India.
For a complete picture of Dengue vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
